The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Methamphetamine Psychosis: Epidemiology and Management
Open accessAbstract
Psychotic symptoms and syndromes are frequently experienced among individuals who use methamphetamine, with recent estimates of up to approximately 40 % of users affected. Although transient in a large proportion of users, acute symptoms can include agitation, violence, and delusions, and may require management in an inpatient psychiatric or other crisis intervention setting. In a subset of individuals, psychosis can recur and persist and may be difficult to distinguish from a primary psychotic disorder such as schizophrenia. Differential diagnosis of primary vs. substance-induced psychotic disorders among methamphetamine users is challenging; nevertheless, with careful assessment of the temporal relationship of symptoms to methamphetamine use, aided by state-of-the art psychodiagnostic assessment instruments and use of objective indicators of recent substance use (i.e., urine toxicology assays), coupled with collateral clinical data gathered from the family or others close to the individual, diagnostic accuracy can be optimized and the individual can be appropriately matched to a plan of treatment. The pharmacological treatment of acute methamphetamine-induced psychosis may include the use of antipsychotic medications as well as benzodiazepines, although symptoms may resolve without pharmacological treatment if the user is able to achieve a period of abstinence from methamphetamine. Importantly, psychosocial treatment for methamphetamine dependence has a strong evidence base and is the optimal first-line treatment approach to reducing rates of psychosis among individuals who use methamphetamines. Prevention of methamphetamine relapse is the most direct means of preventing recurrence of psychotic symptoms and syndromes. Long-term management of individuals presenting with recurrent and persistent psychosis, even in the absence of methamphetamine use, may include both behavioral treatment to prevent resumption of methamphetamine use and pharmacological treatment targeting psychotic symptoms. In addition, treatment of co-occurring psychiatric disorders including depression and anxiety is important as a means of preventing relapse to methamphetamine use, which is often triggered by associated symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For psychostimulant-induced psychosis, psychotic symptoms resolve with abstinence by about 1 week”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as [80]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“whereas primary psychosis will require continued care with antipsychotic medication (80).”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as [80]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“the standard of care for adolescent-and young adult SUD treatment is to use interventions that are specifically tailored or designed for their unique developmental stage.177,178,179”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [178]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
Depression and quality of life in older persons: A review
Sivertsen, H., Bjørkløf, G. H., Engedal, K., Selbæk, G., & Helvik, A.-S. (2015) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000437299 · Cited by 14,152
Robins, L. N. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780290015001 · Cited by 5,219
Robins, L. N. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800360017003 · Cited by 2,909
Leucht, S., Pitschel‐Walz, G., Abraham, D., & Kissling, W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00105-4 · Cited by 795
Provocative tests with psychostimulant drugs in schizophrenia
Lieberman, J. A., Kane, J. M., & Alvir, J. (1987) · Psychopharmacology · doi:10.1007/bf00216006 · Cited by 535
Courtney, K. E., & Ray, L. A. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.08.003 · Cited by 502
Addictions: A Comprehensive Guidebook
McCrady, B. S., & Epstein, E. E. (2013) · Cited by 488
Research works printed but not linked: 6
- World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders. Geneva: Diagnostic Criteria For Research; 1992.
- Connell PH. Amphetamine psychosis. Maudsley Monograph No. 5, London: Oxford University Press; 1958.
- Volkow ND. NIDA research report: methamphetamine abuse and addiction. Washington: National Institute on Drug Abuse; 2006.
- Wada K, Fukui S. Residual symptoms in methamphetamine psychosis. J Mental Health. 1991;37:161–8.
- First MB, Spitzer RL, Williams JEW, et al. Structured Clinical Interview for DSM-IV-Clinician Version (SCID-CV) (User’s guide and interview). Washington, DC: American Psychiatric Press; 1997.
- Rawson RA. Methamphetamine: new knowledge, new treatments. Center City, MN: Hazelden; 2006.
Cited by
Sorted by citations
Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review
Siefried, K. J., Acheson, L. S., Lintzeris, N., & Ezard, N. (2020) · CNS Drugs · doi:10.1007/s40263-020-00711-x · Cited by 194
Pharmacotherapy for methamphetamine/amphetamine use disorder—a systematic review and meta‐analysis
Chan, B., Freeman, M., Kondo, K., Ayers, C., Montgomery, J., Paynter, R., & Kansagara, D. (2019) · Addiction · doi:10.1111/add.14755 · Cited by 160
Wearne, T. A., & Cornish, J. L. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00491 · Cited by 144
A systematic review of risk factors for methamphetamine-associated psychosis
Arunogiri, S., Foulds, J., McKetin, R., & Lubman, D. I. (2018) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867417748750 · Cited by 118
Shin, E., Dang, D., Tran, T.-V., Tran, H., Jeong, J. H., Nah, S.-Y., Jang, C., Yamada, K., Nabeshima, T., & Kim, H. (2017) · Archives of Pharmacal Research · doi:10.1007/s12272-017-0897-y · Cited by 106
Metadata
- Authors
- Glasner-Edwards, S., & Mooney, L. J.
- Affiliations
- University of California, Los Angeles (US)
- ORCID
- Mooney, Larissa J.
- Venue
- CNS Drugs
- Published
- 2014-11-06
- Volume
- 28
- Issue
- 12
- Pages
- 1115-1126
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- PMC
- PMC5027896
- OpenAlex
- W2035893127
- Cited by
- 266
- References
- 97
- Citations by year
- 2026: 26 · 2025: 28 · 2024: 29 · 2023: 34 · 2022: 31 · 2021: 31 · 2020: 18 · 2019: 19 · 2018: 26 · 2017: 9 · 2016: 12 · 2015: 2 · 2014: 1
- FWCI
- 6.04
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Drug Abuse (K23DA020085)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- methamphetamine psychosis, drug-induced psychosis, differential diagnosis, schizophrenia, antipsychotic drugs, benzodiazepines, methamphetamine dependence, psychosocial interventions, relapse prevention, urine toxicology, crisis intervention
- MeSH terms
- Central Nervous System Stimulants, Humans, Methamphetamine, Psychoses, Substance-Induced
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
